Trey Paul is a CNET senior editor covering broadband. His 20+ years of experience as a writer and editor include time at the broadband marketplace Allconnect, as well as working with clients like ...

LONDON, UK I March 17, 2025 I High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary ...